Zhengda Tianqing's first liver imitating MR contrast agent was approved for marketing

On June 12, China biopharmaceutical announced in the evening that the magnetic resonance contrast agent, disodium gadolinate injection, developed by its subsidiary company Zhengda Tianqing, has obtained the drug registration approval issued by the State Drug Administration, which is the first imitation in China China is a country with a high incidence rate of liver diseases The diagnosis and differentiation of liver lesions has become a hot topic in clinical and imaging research According to China biopharmaceutical, disodium gadolinate is a kind of MR contrast agent with liver specificity, which can help to show the structure and patency of the biliary system inside and outside the liver, understand the function of liver cells, and identify different types of liver injury It is helpful to detect liver lesions, especially to improve the detection rate of small liver tumors, so as to facilitate the early diagnosis of liver lesions Cut and treat The preparation of disodium gadolinate has attracted the attention of the industry due to its advantages of accurate effect, convenient use and controllable side effects According to China biopharmaceutical, the first generic disodium gadolinate injection was approved for marketing, which can realize the localization of disodium gadolinate, benefit patients, and further consolidate the dominant position of China biopharmaceutical in the field of liver health.